Abstract:The synthesis of pharmaceutical products frequently involves the use of reactive reagents and the formation of intermediates and by-products. Low levels of some of these may be present in the final drug substance and drug product as impurities. Such chemically reactive impurities may have at the same time the potential for unwanted toxicities including genotoxicity and carcinogenicity and hence can have an impact on product risk assessment. This paper outlines a procedure for testing, classification, qualification, toxicological risk assessment, and control of impurities possessing genotoxic potential in pharmaceutical products. Referencing accepted principles of cancer risk assessment, this document proposes a staged threshold of toxicological concern (TTC) approach for the intake of genotoxic impurities over various periods of exposure. This staged TTC is based on knowledge about tumorigenic potency of a wide range of genotoxic carcinogens and can be used for genotoxic compounds, for which cancer data are limited or not available. The delineated acceptable daily intake values of between approximately 1.5 microg/day for approximately lifetime intake and approximately 120 microg/day for < or = 1 month are virtually safe doses. Based on sound scientific reasoning, these virtually safe intake values do not pose an unacceptable risk to either human volunteers or patients at any stage of clinical development and marketing of a pharmaceutical product. The intake levels are estimated to give an excess cancer risk of 1 in 100,000 to 1 in a million over a lifetime, and are extremely conservative given the current lifetime cancer risk in the population of over 1 in 4 (http://seer.cancer.gov/statfacts/html.all.html). The proposals in this document apply to all clinical routes of administration and to compounds at all stages of clinical development. It is important to note that certain types of products, such as those for life-threatening indications for which there are no safer alternatives, allow for special considerations using adaptations of the principles outlined in this paper.

Role of in silico genotoxicity tools in the regulatory assessment of pharmaceutical impurities

Application of advanced in silico methods for predictive modeling and information integration

In Silico Approaches In Carcinogenicity Hazard Assessment: Current Status and Future Needs

Risk Assessment of Genotoxic Impurities in New Chemical Entities: Strategies To Demonstrate Control

A review on machine learning methods for in silico toxicity prediction

Integration of computational analysis as a sentinel tool in toxicological assessments.

Applying quantitative structure–activity relationship approaches to nanotoxicology: Current status and future potential

In silico toxicology: computational methods for the prediction of chemical toxicity

In silico toxicology protocols

An assessment of mutagenicity of chemical substances by (quantitative) structure–activity relationship

Improvement of quantitative structure–activity relationship (QSAR) tools for predicting Ames mutagenicity: outcomes of the Ames/QSAR International Challenge Project

Understanding and overcoming the technical challenges in using in silico predictions in regulatory decisions of complex toxicological endpoints - A pesticide perspective for regulatory toxicologists with a focus on machine learning models

The importance of expert review to clarify ambiguous situations for (Q)SAR predictions under ICH M7

In Silico Prediction of Chemical Genotoxicity Using Machine Learning Methods and Structural Alerts.

Principles and procedures for handling out-of-domain and indeterminate results as part of ICH M7 recommended (Q)SAR analyses

In silico approaches in organ toxicity hazard assessment: Current status and future needs for predicting heart, kidney and lung toxicities

Assessing the utility of common arguments used in expert review of in silico predictions as part of ICH M7 assessments

Evaluation and Control of Genotoxic Impurities in Active Pharmaceutical Ingredients

GENOTOXIC IMPURITIES: AN IMPORTANT REGULATORY ASPECT

Quantitative structure–toxicity relationships in translational toxicology

A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity